Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Roche's (RHHBY) Lunsumio Application Gets Priority Review
05:17pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.
ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
04:53pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.
Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
08:22pm, Wednesday, 15'th Jun 2022 GlobeNewswire Inc.
WARREN, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care
Aquestive Therapeutics: Sell-Off Prompts A Change In Tactics
10:27am, Thursday, 26'th May 2022
Over the past couple of years, my Aquestive Therapeutics (AQST) thesis has been fixated on valuation and their two most important value drivers, Libervant and AQST-109. AQST-109 is the first and only
Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
12:00pm, Tuesday, 10'th May 2022 GlobeNewswire Inc.
WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care an
Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
08:00am, Tuesday, 10'th May 2022
WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and
Aquestive Therapeutics, Inc. (AQST) Q1 2022 Earnings Call Transcript
06:30pm, Wednesday, 04'th May 2022 The Motley Fool
AQST earnings call for the period ending March 31, 2022.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
10:55pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
09:41pm, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
WARREN, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
08:19pm, Tuesday, 03'rd May 2022
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
12:00pm, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
WARREN, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care
Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions
11:20am, Thursday, 17'th Mar 2022
The FDA has granted Fast Track Designation to Aquestive Therapeutics Inc's (NASDAQ: AQST) AQST-109 for allergic reactions. AQST-109 is an orally delivered epinephrine-based product candidate for the
Aquestive Therapeutics, Inc. (AQST) Q4 2021 Earnings Call Transcript
10:30pm, Wednesday, 09'th Mar 2022 The Motley Fool
AQST earnings call for the period ending December 31, 2021.
Aquestive Therapeutics, Inc. (AQST) Q4 2021 Earnings Call Transcript
10:30pm, Wednesday, 09'th Mar 2022 The Motley Fool
AQST earnings call for the period ending December 31, 2021.
